Lawmakers in the United States have raised alarms about the escalating dependence of the US drug supply on pharmaceutical ingredients sourced from China. This growing reliance is compared to previous concerns over China’s control of supply chains for critical materials like rare earths and semiconductors. Discussions during a recent congressional hearing emphasized that this issue is not only about current dependencies but also about a deliberate strategy by China to increase its dominance in the pharmaceutical sector.

The hearing, featuring Florida Republican Neal Dunn and other lawmakers, scrutinized China’s intentions and strategies to expand its pharmaceutical industry. Dunn accused China of having a systematic plan to climb the pharmaceutical value chain, projecting significant growth in revenue for the sector—estimated to soar by 50% from 2024 to 2030. This anticipated boom is attributed to China’s ageing population and its ambitions for global expansion in the medical and pharmaceutical fields.

As China’s drug and medical device industries are predicted to generate upwards of $2.1 trillion in revenue by 2030, the implications for US national security and health care become increasingly concerning. This dependence raises questions about supply chain vulnerabilities, as US lawmakers consider the potential risks of relying heavily on foreign ingredients for essential medicines. The overarching theme from the hearing suggests a call for strategic reassessment of US pharmaceutical dependencies on China.